Key result
Review details the pathophysiology, epidemiology, and management of valvular heart disease in HFpEF.
Why the study?
Recent advances in percutaneous therapies for VHD and an improved understanding of HFpEF have heightened interest in the relationship between these frequently co-occurring conditions.
This review summarizes the pathophysiology, epidemiology, and management of valvular heart disease in the context of heart failure with preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
Supports valvular assessment in HFpEF; leaves open dedicated intervention trials.
Heart failure with preserved ejection fraction (HFpEF) is associated with reduced functional capacity and quality of life, as well as with high rates of heart failure hospitalisation and mortality. Valvular heart disease (VHD) is frequently encountered in patients with HFpEF, and both conditions share common risk factors, such as age, hypertension, diabetes and coronary artery disease, which may contribute to their shared pathogenesis and progression. With recent advances in percutaneous therapies for VHD and an improved understanding of HFpEF, there is a growing interest in the relationship between VHD and HFpEF. In this review, we provide an overview of the pathophysiology, epidemiology and management strategies of tricuspid regurgitation, mitral regurgitation, aortic stenosis and aortic regurgitation in the setting of HFpEF.
No takes yet. Share an insight, caveat, or question.
Adeli et al. (2026) conducted a review in Heart failure with preserved ejection fraction and valvular heart disease. Valvular heart disease was evaluated. This review provides an overview of the pathophysiology, epidemiology, and management strategies of valvular heart disease in the setting of heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: